Journal Article

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Ignatiadis, Michail, Clatot, Florent, Sotiriou, Christos, Duhoux, Francois P., Paesmans, Marianne, Piccart-Gebhart, Martine, Barthélémy, Philippe, Kristanto, Paulus, Canon, Jean-Luc, Salgado, Roberto, Ferrero, Jean-Marc, Buisseret, Laurence, Poncin, Renaud, Goncalves, Anthony, Van den Mooter, Tom, Ghiringhelli, François, Taylor, Donatienne, Isambert, Nicolas, Denis, Zoë, Mansi, Laura, Catteau, Xavier, Craciun, Ligia, Venet, David, Stagg, John, Eiger, Daniel, Aftimos, Philippe, Maurer, Christian, Agostinetto, Elisa, Debien, Véronique, Rothé, Françoise, Punie, Kevin, Larsimont, Denis, Bonnefoi, Hervé, Loirat, Delphine, de Azambuja, Evandro, Romano, Emanuela

2023

Overview

Chemo-immunotherapy is the first-line standard of care for patients with PD-L1 positive metastatic triple-negative breast cancer (mTNBC). SYNERGY (NCT03616886) is a dose-finding phase I and a randomized phase II, open-label trial evaluating if targeting the immunosuppressive adenosine pathway can enhance the antitumor activity of chemo-immunotherapy. The phase I part included 6 patients with untreated locally-advanced or mTNBC to determine the safety and recommended phase II dose of the anti-CD73 antibody oleclumab in combination with the anti-PD-L1 durvalumab and 12 cycles of weekly carboplatin and paclitaxel. In the phase II part, 127 women were randomized 1:1 to receive chemo-immunotherapy, with (arm A) or without (arm B) oleclumab. The primary endpoint was the clinical benefit rate at week 24, defined as stable disease, partial or complete response per RECIST v1.1. Secondary endpoints included objective response rate, duration of response, survival outcomes (progression-free survival and overall survival), and safety. The trial did not meet its primary endpoint, as the 24-week clinical benefit rate was not significantly improved by adding oleclumab (43% vs. 44%, p  = 0.61). Exploratory median progression-free survival was 5.9 months in arm A as compared to 7.0 months in arm B ( p  = 0.90). The safety profile was manageable in both arms. Preclinical studies have shown that blockade of the CD73-adenosinergic pathway could improve anti-tumor immunity and response to other immune checkpoint inhibitors. Here the authors report the results of a randomized phase II trial of first-line durvalumab, paclitaxel and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced triple-negative breast cancer.

• Publisher: Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
• Subject: 631/67/1347 / 692/4028/67/1059/2325 / 692/4028/67/1347 / 82/51 / Adenosine / Antibodies / Anticancer properties / Antineoplastic Agents - therapeutic use / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antitumor activity / Breast cancer / Carboplatin / Carboplatin - therapeutic use / CD73 antigen / Female / Humanities and Social Sciences / Humans / Immune checkpoint inhibitors / Immunotherapy / Metastases / Metastasis / Monoclonal antibodies / multidisciplinary / Paclitaxel / Paclitaxel - therapeutic use / PD-L1 protein / Safety / Safety management / Science / Science (multidisciplinary) / Survival / Targeted cancer therapy / Triple Negative Breast Neoplasms - drug therapy / Triple Negative Breast Neoplasms - pathology